| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012436727 |
| P356 | DOI | 10.1111/J.1523-1755.2005.00600.X |
| P698 | PubMed publication ID | 16164659 |
| P5875 | ResearchGate publication ID | 7597798 |
| P2093 | author name string | Paolo Raggi | |
| David M Spiegel | |||
| Geoffrey A Block | |||
| James Ehrlich | |||
| Albert Dreisbach | |||
| Ravindra Mehta | |||
| Jill Lindbergh | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hemodialysis patient | Q126109077 |
| patient | Q181600 | ||
| P304 | page(s) | 1815-1824 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis | |
| P478 | volume | 68 |
| Q37785186 | A Synopsis of Phosphate Disorders in the Nursing Home |
| Q37845417 | A daunting task but largely successful in developing meaningful guidelines |
| Q35015899 | A low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients |
| Q36669045 | A new era in phosphate binder therapy: what are the options? |
| Q37276108 | A rat model of chronic kidney disease-mineral bone disorder |
| Q37090480 | Abdominal aortic calcification in dialysis patients: results of the CORD study |
| Q92838728 | Adenovirus-expressing miR-153-3p alleviates aortic calcification in a rat model with chronic kidney disease |
| Q46162426 | Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats |
| Q38587575 | Advances in pharmacotherapy for hyperphosphatemia in renal disease |
| Q35985691 | All-cause mortality in hemodialysis patients with heart valve calcification |
| Q83641432 | Aortic arch calcification evaluated on chest X-ray is a strong independent predictor of cardiovascular events in chronic hemodialysis patients |
| Q39071314 | Arterial Calcification in Diabetes Mellitus: Preclinical Models and Translational Implications. |
| Q52358290 | Arterial stiffness in end-stage renal disease-pathogenesis, clinical epidemiology, and therapeutic potentials. |
| Q41103027 | Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial |
| Q35024959 | Association of Serum Phosphate and Related Factors in ESRD-Related Vascular Calcification |
| Q36842378 | Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. |
| Q92739798 | Association of mineral content outside of bone with coronary artery calcium and 1-year cardiovascular prognosis in maintenance hemodialysis patients |
| Q53242888 | Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. |
| Q84962230 | Beyond phosphate binding: the effect of binder therapy on novel biomarkers may have clinical implications for the management of chronic kidney disease patients |
| Q47738927 | Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. |
| Q37697926 | CKD-mineral and bone disorder: core curriculum 2011. |
| Q45002024 | Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells |
| Q46432103 | Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism |
| Q48038085 | Calcium Homeostasis in Health and in Kidney Disease |
| Q27687570 | Calcium and phosphate impact cardiovascular risk |
| Q37287364 | Calcium and the saga of the binders: accumulating controversy, or building consensus? |
| Q37350988 | Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy |
| Q33837633 | Calcium balance and negative impact of calcium load in peritoneal dialysis patients |
| Q38807535 | Calcium supplementation and cardiovascular risk: A rising concern |
| Q37223483 | Calcium supplementation and vascular disease. |
| Q38240989 | Calcium supplementation in chronic kidney disease |
| Q37995894 | Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease |
| Q51614592 | Can Intestinal Phosphate Binding or Inhibition of Hydroxyapatite Growth in the Vascular Wall Halt the Progression of Established Aortic Calcification in Chronic Kidney Disease? |
| Q37787773 | Can we reduce the cardiovascular risk in peritoneal dialysis patients? |
| Q91784498 | Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis |
| Q84563746 | Cardiovascular disease in patients with chronic kidney disease |
| Q38389206 | Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders |
| Q35679887 | Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? |
| Q37877789 | Cardiovascular risk in diabetic end-stage renal disease patients |
| Q30473207 | Carotid artery calcification at the initiation of hemodialysis is a risk factor for cardiovascular events in patients with end-stage renal disease: a cohort study |
| Q36765398 | Causes and consequences of increased arterial stiffness in chronic kidney disease patients |
| Q91924585 | Cerebrovascular events in hemodialysis patients; a retrospective observational study |
| Q87041755 | Chapter 3.1: Diagnosis of CKD-MBD: biochemical abnormalities |
| Q87041760 | Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium |
| Q55234385 | Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification. |
| Q38016491 | Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications |
| Q37119068 | Chronic kidney disease in children. |
| Q24642788 | Chronic kidney disease mineral and bone disorder in children |
| Q34402661 | Chronic kidney disease: mineral and bone disorder in children |
| Q33562186 | Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. |
| Q38041980 | Circulating vitamin D, calcium and risk of cerebrovascular disease: a systematic review and meta-analysis |
| Q33610457 | Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients |
| Q43292194 | Clinical assessment of atherosclerotic parameters and cardiac function in chronic hemodialysis patients |
| Q38784139 | Clinical features of CKD-MBD in Japan: cohort studies and registry |
| Q43427754 | Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder |
| Q36837874 | Clinical, cellular, and molecular aspects of arterial calcification |
| Q33801022 | Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D |
| Q36497902 | Con: Phosphate binders in chronic kidney disease |
| Q38364975 | Con: vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease |
| Q38511621 | Contemporary management of phosphorus retention in chronic kidney disease: a review |
| Q79811083 | Control of hyperphosphatemia beyond phosphate |
| Q64951187 | Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study. |
| Q46405649 | Coronary artery calcification and mortality in diabetic patients with proteinuria |
| Q39317309 | Coronary artery calcification in Korean patients with incident dialysis |
| Q37722763 | Coronary artery calcification in chronic kidney disease: An update. |
| Q35025394 | Coronary artery calcification scores in patients with chronic kidney disease prior to dialysis: reliability as a trial outcome measure |
| Q41486652 | Coronary artery calcification, cardiovascular events, and death: a prospective cohort study of incident patients on hemodialysis |
| Q81692061 | Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging |
| Q36805506 | Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. |
| Q80217881 | Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients |
| Q50187886 | Deletion of IκB-Kinase β in Smooth Muscle Cells Induces Vascular Calcification Through β-Catenin-Runt-Related Transcription Factor 2 Signaling |
| Q41389097 | Design and baseline characteristics of the LANDMARK study |
| Q37042079 | Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients |
| Q90237333 | Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease |
| Q55072659 | Does Sevelamer Hydrochloride (Renagel) Influence 25(Oh)D3 and 1,25(Oh)2D3 Level in Haemodialysis Patients? |
| Q80442302 | Does Sevelamer reduce mortality by slowing of progression of coronary calcification? |
| Q33840398 | Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study |
| Q99584598 | Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial |
| Q57216624 | Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients |
| Q38122834 | Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis |
| Q35983529 | Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients |
| Q46980859 | Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study. |
| Q57219337 | Effectiveness and cost-efficacy of phosphate binders in hemodialysis |
| Q38132834 | Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate. |
| Q50067183 | Effects of Lanthanum Carbonate on Coronary Artery Calcification and Cardiac Abnormalities After Initiating Hemodialysis |
| Q46322350 | Effects of atorvastatin on warfarin-induced aortic medial calcification and systolic blood pressure in rats |
| Q40068197 | Effects of serum calcium and magnesium on heart rate variability in adult women |
| Q46983889 | Effects of sevelamer and calcium on coronary artery calcification in patients new to dialysis: time for better controlled clinical trials |
| Q35576119 | Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease |
| Q57218116 | Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study |
| Q86611573 | Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure |
| Q34724266 | Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy. |
| Q84020635 | Efficacy and safety of SBR759, a new iron-based phosphate binder |
| Q46344305 | Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis |
| Q36736647 | Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis |
| Q38219038 | Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients |
| Q37613856 | Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia |
| Q53241475 | Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. |
| Q33345061 | Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? |
| Q36944004 | Emerging drugs for hyperphosphatemia. |
| Q41503537 | Epicardial adipose tissue in long-term hemodialysis patients: its association with vascular calcification and long-term development |
| Q50857969 | Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium-based phosphate binders: a substudy of the Renagel in new dialysis trial. |
| Q34576615 | Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial |
| Q44328455 | Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial |
| Q34213692 | Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability |
| Q33615078 | Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis. |
| Q88421208 | Evidence basis for integrated management of mineral metabolism in patients with end-stage renal disease |
| Q38179484 | Extraosseous calcification in end-stage renal disease: from visceral organs to vasculature |
| Q38031216 | FGF-23: the rise of a novel cardiovascular risk marker in CKD. |
| Q53646564 | Feasibility study of colestipol as an oral phosphate binder in hemodialysis patients. |
| Q31038421 | Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul Study |
| Q57044355 | First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification |
| Q47843993 | High serum phosphorus and FGF 23 levels are associated with progression of coronary calcifications |
| Q103028972 | High-phosphorus diets reduce aortic lesions and cardiomyocyte size and modify lipid metabolism in Ldl receptor knockout mice |
| Q37845421 | How KDIGO will (or will not) influence the management of hyperphosphatemia |
| Q38092144 | Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy. |
| Q38102603 | Hyperphosphataemia: treatment options |
| Q26830013 | Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence |
| Q28081229 | Hyperphosphatemia. The hidden killer in chronic kidney disease |
| Q36606586 | Hypophosphatemic effect of niacin extended release in ischemic kidney disease |
| Q33770086 | Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial |
| Q49385302 | Impact of trajectories of abdominal aortic calcification over 2 years on subsequent mortality: a 10-year longitudinal study. |
| Q34576693 | Incidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study of Atherosclerosis |
| Q91893228 | Increased Risk of Infection-Related and All-Cause Death in Hypercalcemic Patients Receiving Hemodialysis: The Q-Cohort Study |
| Q41607947 | Increased risk of cardiovascular events in end-stage renal disease patients with osteoporosis: a nationwide population-based cohort study |
| Q35733003 | Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients (iPACK-HD) trial: rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease |
| Q38671509 | Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders. |
| Q36688447 | Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis |
| Q53238034 | Intracranial arterial calcification is highly prevalent in hemodialysis patients but does not associate with acute ischemic stroke. |
| Q36669039 | Introduction: improving outcomes in chronic kidney disease. |
| Q38295285 | Iron-based phosphate binders--a new element in management of hyperphosphatemia. |
| Q37087925 | Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. |
| Q37739818 | Ironing out the phosphorus problem |
| Q37228193 | Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questions |
| Q35664616 | Kinetic model of phosphorus mobilization during and after short and conventional hemodialysis |
| Q46643014 | Lack of mortality benefit with sevelamer |
| Q39430387 | Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study |
| Q36831509 | Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis |
| Q37063372 | Long-term outcome of chronic dialysis in children |
| Q36338922 | Lower serum magnesium is associated with vascular calcification in peritoneal dialysis patients: a cross sectional study |
| Q42718947 | Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival |
| Q35107539 | Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells |
| Q64071724 | Malnutrition, inflammation, progression of vascular calcification and survival: Inter-relationships in hemodialysis patients |
| Q26781361 | Management of chronic kidney disease-mineral and bone disorder: Korean working group recommendations |
| Q35608435 | Management of hyperphosphataemia in chronic kidney disease-challenges and solutions |
| Q26866391 | Management of hyperphosphataemia in chronic kidney disease: summary of National Institute for Health and Clinical Excellence (NICE) guideline |
| Q35026657 | Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate. |
| Q36632228 | Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs |
| Q42727533 | Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation |
| Q36994038 | Mineral metabolic abnormalities and mortality in dialysis patients |
| Q37843788 | Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes |
| Q36817218 | Mineral metabolism and cortical volumetric bone mineral density in childhood chronic kidney disease |
| Q36884206 | Mineral metabolism disturbances in patients with chronic kidney disease |
| Q45738060 | Mitral annular calcification in patients undergoing aortic valve replacement for aortic valve stenosis |
| Q79478108 | Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients |
| Q35730847 | New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials |
| Q37111857 | New strategies for the treatment of hyperparathyroidism incorporating calcimimetics |
| Q57219101 | Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects |
| Q30277401 | Noninvasive Cardiovascular Risk Assessment of the Asymptomatic Diabetic Patient: The Imaging Council of the American College of Cardiology |
| Q37921598 | Noninvasive imaging for assessment of calcification in chronic kidney disease |
| Q36225208 | Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease |
| Q36669053 | Novel insights into vascular calcification |
| Q57771987 | Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease |
| Q38161580 | Optimal use of phosphate binders in chronic kidney disease |
| Q42727549 | Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder. |
| Q37412918 | Oral phosphate binders |
| Q35059741 | Osteo-renal regulation of systemic phosphate metabolism |
| Q35995048 | Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients |
| Q30433029 | Outcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney disease |
| Q38593558 | Pathophysiology of Vascular Calcification |
| Q36833143 | Patient education for phosphorus management in chronic kidney disease |
| Q34669852 | Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. |
| Q51015087 | Peritoneal delivery of sodium pyrophosphate blocks the progression of pre-existing vascular calcification in uremic apolipoprotein-E knockout mice. |
| Q90015267 | Pharmacologic Therapies for Aortic Stiffness in End-Stage Renal Disease: A Systematic Review and Meta-Analysis |
| Q38824573 | Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease |
| Q37948105 | Pharmacotherapy of chronic kidney disease and mineral bone disorder. |
| Q33531889 | Pharmacotherapy of end-stage renal disease |
| Q39033792 | Phosphate Binders and Targets Over Decades: Do We have it Right Now? |
| Q42746251 | Phosphate Metabolism in CKD Stages 3-5: Dietary and Pharmacological Control |
| Q33566596 | Phosphate and cardiovascular disease |
| Q55507997 | Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1. |
| Q38253227 | Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool. |
| Q24234036 | Phosphate binders for preventing and treating bone disease in chronic kidney disease patients |
| Q24244049 | Phosphate binders for preventing and treating bone disease in chronic kidney disease patients |
| Q57213546 | Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD) |
| Q38202179 | Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles |
| Q37629694 | Phosphate binders in CKD: chalking out the differences. |
| Q42044079 | Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure |
| Q36522027 | Phosphate binders: new products and challenges |
| Q27025339 | Phosphate control in dialysis |
| Q33562017 | Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin |
| Q38009044 | Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk |
| Q38060627 | Phosphate is a vascular toxin |
| Q43473250 | Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification |
| Q37492019 | Phosphate: an old bone molecule but new cardiovascular risk factor |
| Q49846193 | Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial. |
| Q35078539 | Plasma pyrophosphate and vascular calcification in chronic kidney disease |
| Q36669049 | Pleiotropic effects of the non-calcium phosphate binder sevelamer. |
| Q53116786 | Polymorphism in the human matrix Gla protein gene is associated with the progression of vascular calcification in maintenance hemodialysis patients. |
| Q26777613 | Pre-treatment considerations in childhood hypertension due to chronic kidney disease |
| Q98612947 | Presepsin Level Correlates with the Development of Moderate Coronary Artery Calcifications in Hemodialysis Patients: A Preliminary Cross-Section Design Study |
| Q49683014 | Prevalence of Calcification in Human Femoropopliteal Arteries and its Association with Demographics, Risk Factors, and Arterial Stiffness |
| Q34497204 | Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study |
| Q37087856 | Pulse pressure and presence of coronary artery calcification |
| Q36583383 | Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients |
| Q88494286 | Rationale to reduce calcium intake in adult patients with chronic kidney disease |
| Q26849298 | Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease |
| Q35247898 | Recent progress in the treatment of vascular calcification |
| Q42371213 | Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis. |
| Q37073515 | Relation of serum fetuin-A levels to coronary artery calcium in African-American patients on chronic hemodialysis. |
| Q87624174 | Relationship between cardiac calcification and left ventricular hypertrophy in patients with chronic kidney disease at hemodialysis initiation |
| Q35013412 | Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study |
| Q37740980 | Renal function had an independent relationship with coronary artery calcification in Chinese elderly men. |
| Q37207904 | Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols |
| Q95360397 | Risk factors associated with aortic calcification in hemodialysis patients |
| Q33611410 | Risk factors of one year increment of coronary calcifications and survival in hemodialysis patients |
| Q64970894 | Role of Albumin Assay on Calcium Levels and Prescription of Phosphate Binders in Chronic Hemodialysis Patients. |
| Q47709791 | SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels |
| Q35351243 | Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis |
| Q47152101 | Scientific Opinion on the Tolerable Upper Intake Level of calcium |
| Q43155195 | Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study |
| Q53501998 | Serum levels of calcification inhibition proteins and coronary artery calcium score: comparison between transplantation and dialysis. |
| Q34505136 | Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials |
| Q80599557 | Sevelamer and extension studies |
| Q37641046 | Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation |
| Q37643107 | Sevelamer carbonate |
| Q36283544 | Sevelamer carbonate experience in Indian end stage renal disease patients |
| Q37803240 | Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III – V) |
| Q43252071 | Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients |
| Q36951232 | Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients |
| Q38210438 | Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease |
| Q36443804 | Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. |
| Q37032561 | Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis |
| Q38231646 | Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential. |
| Q38229798 | Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study |
| Q37567574 | Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease |
| Q80467002 | Should clinicians follow the K/DOQI guidelines for treating hyperphosphatemia with sevelamer? |
| Q52674810 | Should nephrologists consider vascular calcification screening? |
| Q80533147 | Should we be using calcium-containing phosphate binders in patients on dialysis? |
| Q92803503 | Strategies for Phosphate Control in Patients With CKD |
| Q44471363 | Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia |
| Q53524086 | Teriparatide Therapy Reduces Serum Phosphate and Intima-Media Thickness at the Carotid Wall Artery in Patients with Osteoporosis. |
| Q64235923 | The Bone-Vasculature Axis: Calcium Supplementation and the Role of Vitamin K |
| Q37670856 | The Strategy to Prevent and Regress the Vascular Calcification in Dialysis Patients. |
| Q36466078 | The association between mortality and abdominal aortic calcification and relation between its progression and serum calcium concentration in chronic hemodialysis patients. |
| Q45996029 | The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. |
| Q36214854 | The demise of calcium-based phosphate binders-is this appropriate for children? |
| Q34885173 | The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol |
| Q37734160 | The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study |
| Q38229088 | The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials |
| Q38819231 | The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis |
| Q33595584 | The emerging role of phosphate in vascular calcification |
| Q26782816 | The health benefits of vitamin K |
| Q53535993 | The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. |
| Q36677622 | The mechanism of phosphorus as a cardiovascular risk factor in CKD |
| Q36577167 | The mechanism of vascular calcification - a systematic review. |
| Q42600857 | The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification |
| Q35561373 | The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study |
| Q26823897 | The role of phosphorus in the development and progression of vascular calcification |
| Q36566674 | Therapeutic strategies for secondary hyperparathyroidism in dialysis patients. |
| Q57220755 | Therapeutic use of the phosphate binder lanthanum carbonate |
| Q37362689 | Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification. |
| Q26823146 | Toward individualized cholesterol-lowering treatment in end-stage renal disease |
| Q38958363 | Treating hyperphosphatemia - current and advancing drugs |
| Q33387235 | Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data. |
| Q35026640 | Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs |
| Q38160473 | Update and critical appraisal of sevelamer in the management of chronic renal failure |
| Q58578167 | Update on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease |
| Q36438126 | Urine calcium excretion, cardiovascular events, and mortality in outpatients with stable coronary artery disease (from the Heart and Soul study). |
| Q37914009 | Vascular and valvular calcification in chronic peritoneal dialysis patients |
| Q36930927 | Vascular calcification and arterial stiffness in chronic kidney disease: implications and management |
| Q39009566 | Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho |
| Q53165605 | Vascular calcification in South African dialysis patients: ethnic variation, prevalence, detection and haemodynamic correlates. |
| Q53527834 | Vascular calcification in chronic kidney disease: an update. |
| Q34037021 | Vascular calcification in chronic kidney disease: role of disordered mineral metabolism |
| Q34566734 | Vascular calcification on plain radiographs is associated with carotid intima media thickness, malnutrition and cardiovascular events in dialysis patients: a prospective observational study |
| Q79273202 | Vascular calcification: Hardening of the evidence |
| Q28071582 | Vascular calcification: When should we interfere in chronic kidney disease patients and how? |
| Q37649134 | Vascular calcification: pathophysiology and risk factors |
| Q34587149 | Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial |
| Q37941837 | Vitamin d and stage 5 chronic kidney disease: a new paradigm? |
| Q83941120 | [Cardiorenal syndrome] |
| Q83879599 | [Vascular calcification and arteriosclerosis in chronic kidney disease patients] |
| Q42539832 | p53 negatively regulates the osteogenic differentiation of vascular smooth muscle cells in mice with chronic kidney disease |
Search more.